AU2021260142A1 - H4 antagonist compounds - Google Patents

H4 antagonist compounds Download PDF

Info

Publication number
AU2021260142A1
AU2021260142A1 AU2021260142A AU2021260142A AU2021260142A1 AU 2021260142 A1 AU2021260142 A1 AU 2021260142A1 AU 2021260142 A AU2021260142 A AU 2021260142A AU 2021260142 A AU2021260142 A AU 2021260142A AU 2021260142 A1 AU2021260142 A1 AU 2021260142A1
Authority
AU
Australia
Prior art keywords
over
pyrazol
methyl
pyrimidin
azetidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021260142A
Other languages
English (en)
Inventor
Miles Stuart Congreve
Charlotte Fieldhouse
Duncan Robert Hannah
Mark PICKWORTH
Nigel Alan Swain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70859977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2021260142(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of AU2021260142A1 publication Critical patent/AU2021260142A1/en
Assigned to NXERA PHARMA UK LIMITED reassignment NXERA PHARMA UK LIMITED Amend patent request/document other than specification (104) Assignors: HEPTARES THERAPEUTICS LIMITED
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021260142A 2020-04-22 2021-04-22 H4 antagonist compounds Pending AU2021260142A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005858.2 2020-04-22
GBGB2005858.2A GB202005858D0 (en) 2020-04-22 2020-04-22 H4 Antagonist compounds
PCT/GB2021/050971 WO2021214469A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds

Publications (1)

Publication Number Publication Date
AU2021260142A1 true AU2021260142A1 (en) 2022-11-17

Family

ID=70859977

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021260142A Pending AU2021260142A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds

Country Status (12)

Country Link
US (1) US20230167094A1 (https=)
EP (1) EP4139300A1 (https=)
JP (1) JP7671307B2 (https=)
KR (1) KR20230004512A (https=)
CN (1) CN115916770B (https=)
AU (1) AU2021260142A1 (https=)
BR (1) BR112022021395A2 (https=)
CA (1) CA3180853A1 (https=)
GB (1) GB202005858D0 (https=)
IL (1) IL297469A (https=)
MX (1) MX2022013340A (https=)
WO (1) WO2021214469A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) * 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (es) * 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina
GB201817047D0 (en) * 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds

Also Published As

Publication number Publication date
CN115916770A (zh) 2023-04-04
MX2022013340A (es) 2023-02-22
JP2023522405A (ja) 2023-05-30
KR20230004512A (ko) 2023-01-06
BR112022021395A2 (pt) 2022-12-13
GB202005858D0 (en) 2020-06-03
WO2021214469A1 (en) 2021-10-28
EP4139300A1 (en) 2023-03-01
CN115916770B (zh) 2025-02-28
JP7671307B2 (ja) 2025-05-01
IL297469A (en) 2022-12-01
US20230167094A1 (en) 2023-06-01
CA3180853A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP2997023B1 (en) Bipyrazole derivatives as jak inhibitors
AU2020413997A1 (en) Pyridazinyl-thiazolecarboxamide compound
WO2018228275A1 (zh) 作为mnk抑制剂的杂环化合物
WO2013026025A1 (en) Cyclohexyl azetidine derivatives as jak inhibitors
JP7532353B2 (ja) Ｈ４アンタゴニスト化合物としてのピラゾール誘導体
US10556911B2 (en) Thienopyrimidine compounds
EP4139300A1 (en) H4 antagonist compounds
RU2837355C1 (ru) Соединения-антагонисты н4
CN118574825A (zh) 作为fak抑制剂的化合物及其用途
JP7764479B2 (ja) Ｈ４アンタゴニスト化合物
CN112209933B (zh) 含有4-氮杂螺庚烷的btk抑制剂
RU2821516C2 (ru) Пиразольные производные в качестве соединений-антагонистов h4
WO2026062171A1 (en) Pyridopyrimidine derivative as histamine receptor inhibitor
WO2026021342A1 (zh) 一种杂环类化合物及其在医药上的应用
HK1221466B (en) Bipyrazole derivatives as jak inhibitors

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NXERA PHARMA UK LIMITED

Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED